On April 1, 2024 DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, reported multiple upcoming poster and oral presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place in San Diego, California, from April 5-10, 2024 (Press release, Delfi Diagnostics, APR 1, 2024, View Source [SID1234641677]). DELFI and independent researchers will highlight the performance of the company’s next-generation, fragmentomics-based liquid biopsy platform to help detect early cancer and monitor treatment response.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"DELFI’s robust presence at AACR (Free AACR Whitepaper) this year reflects our substantial clinical progress in demonstrating the DELFI platform’s high performance in a range of applications across multiple tumor types," said Susan Tousi, DELFI Chief Executive Officer. "We’re excited to share additional clinical validation data for FirstLook Lung, the first and only screening test of its kind for early lung cancer detection, as we actively expand commercial partnerships with select U.S. health systems. Patients need better cancer screening and treatment-monitoring options, while health systems and payers need affordable and broadly accessible tests that improve patient outcomes. Our multiple datasets at AACR (Free AACR Whitepaper) will showcase DELFI’s expansive and differentiated potential in these areas."
DELFI will be located at AACR (Free AACR Whitepaper) Booth 947. Individual session details follow:
Presenter
Title
Session Title
Session
Date
Session
Time
Location
Poster
Board
Number
Published
Abstract
Number
Rob
Scharpf
Models and Prediction
ED01 – Data Science Opportunities and Challenges in Biomarker-based Early Detection of Cancer
4/6/2024
8:30 AM-8:50 AM
Ballroom 6 CF – Upper Level
NA
NA
Rob
Scharpf
NA
ED01 – Data Science Opportunities and Challenges in Biomarker-based Early Detection of Cancer
4/6/2024
8:00 AM- 9:30 AM
Ballroom 6 CF – Upper Level
NA
NA
Lindsey
Cotton
Clinical validation: A blood-based biomarker for early lung cancer detection based on circulating DNA fragmentomics
Early Detection Biomarkers I
4/7/2024
1:30-5PM
Poster Section 43
10
1062
Peter
Bach
Projected impact of liquid biopsy screening strategies with high sensitivity in focused populations and high specificity in broad populations
Multi-Cancer Early Detection Testing: Where Are We?
4/7/2024
4:05 PM – 4:20 PM
Room 28 – Upper Level
N/A
1267
Stephen Cristiano
Robustness of fragmentation-based cell-free DNA approaches to clonal hematopoiesis
Circulating Nucleic Acids 1
4/7/2024
1:30 PM – 5:00 PM
Poster Section 40
22
981
Akshaya Annapragada
Genome-wide repeat landscapes in cancer and cell-free DNA
Circulating Nucleic Acids 1
4/7/2024
1:30 PM – 5:00 PM
Poster Section 40
29
988
Carlie
Hruban
Liquid biopsy approaches for monitoring metastatic pancreatic cancer in immunotherapy treated patients
Circulating Nucleic Acids 2
4/8/2024
9:00 AM – 12:30 PM
Poster Section 40
18
2422
Bahar Alipanahi
Monitoring response to immunotherapy using cell-free DNA fragmentomes
Circulating Tumor Cells 1
4/8/2024
1:30 PM – 5:00 PM
Poster Section 42
7
3695
Denise
Van
Steijn
Monitoring treatment response in patients with metastatic colorectal cancer using cfDNA fragmentomics testing: the DOLPHIN trial
Circulating Nucleic Acids 3
4/8/2024
1:30-5PM
Poster Section 41
18
3673
Victor Velculescu
Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers
Press Conference
4/9/2024
8:30 AM
Room 26
NA
NA
Nick
Vulpescu
Chromatin landscapes of colorectal cancer development and cfDNA fragmentation
Characterization of Mutational Processes and Drivers in Cancer Development and Evolution
4/9/2024
9:00 AM – 12:30 PM
Poster Section 15
9
4339
Victor Velculescu
Early detection of cancer using cell-free DNA fragmentomes
AT07 – New Liquid Biopsy Technologies for Detection and Characterization of Cancer
4/9/2024
1:25 PM – 1:45 PM
Ballroom 20 CD – Upper Level
NA
NA
Victor Velculescu
NA
AT07 – New Liquid Biopsy Technologies for Detection and Characterization of Cancer
4/9/2024
12:30 PM – 2:00 PM
Ballroom 20 CD – Upper Level
NA
NA
Jamie
Medina
and
Akshaya Annapragada
Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers
Biomarker-Based Screening
4/9/2024
1:30 PM – 5:00 PM
Poster Section 31
12
6086